Although several possible mechanisms for the combination of PD-L1/PD-1 and VEGF blockades have been reported using anti-PD-L1/PD-1 blockade-sensitive models (17–19), to the best of our knowledge, no studies have used a PD-L1low and immune desert-like tumor model. The gene discussed is PDCD1; the disease is neoplasm.